Clearside Biomedical, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.14 | -$0.14 | -$0.14 |
| Q2 2024 | 3 | -$0.14 | -$0.14 | -$0.14 |
| Q3 2024 | 5 | -$0.14 | -$0.12 | -$0.12 |
| Q4 2024 | 3 | -$0.11 | -$0.11 | -$0.11 |
| Q1 2025 | 4 | -$0.11 | -$0.11 | -$0.11 |
| Q2 2025 | 4 | -$0.12 | -$0.12 | -$0.12 |
| Q3 2025 | 4 | -$0.15 | -$0.15 | -$0.15 |
| Q4 2025 | 4 | -$0.17 | -$0.17 | -$0.17 |
Clearside Biomedical, Inc. Earnings Date And Information
Clearside Biomedical, Inc. last posted its earnings results on Monday, August 12th, 2024. The company reported $-0.1 earnings per share for the quarter, topping analysts' consensus estimates of $-0.14 by $0.04. The company had revenue of 1.04 M for the quarter and had revenue of 8.23 M for the year. Clearside Biomedical, Inc. has generated $-1 earnings per share over the last year ($-0.53 diluted earnings per share) and currently has a price-to-earnings ratio of -2.53. Clearside Biomedical, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 12th, 2024 based on prior year's report dates.
Clearside Biomedical, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/12/2024 | Q3 2024 | -$0.10 | $130,000 | $1.04 M | ||
| 08/12/2024 | Q2 2024 | -$0.14 | -$0.10 | 0.04 | $126,500 | $90,000 |
| 05/10/2024 | Q1 2024 | -$0.17 | $230,000 | |||
| 03/12/2024 | Q4 2023 | -$0.10 | -$0.08 | 0.02 | $6.35 M | |
| 11/13/2023 | Q3 2023 | -$0.16 | -$0.15 | 0.01 | $166,667 | $859,000 |
| 08/14/2023 | Q2 2023 | -$0.14 | -$0.15 | -0.01 | $103,500 | $1.02 M |
| 05/12/2023 | Q1 2023 | -$0.21 | $4,000 | |||
| 03/14/2023 | Q4 2022 | -$0.14 | $330,000 | |||
| 11/09/2022 | Q3 2022 | -$0.03 | -$0.13 | -0.1 | $8.15 M | $266,000 |
| 08/12/2022 | Q2 2022 | -$0.13 | $375,000 | $384,000 | ||
| 05/12/2022 | Q1 2022 | -$0.13 | $347,000 | |||
| 03/11/2022 | Q4 2021 | $0.31 | $25.69 M | |||
| 11/10/2021 | Q3 2021 | -$0.09 | -$0.08 | 0.01 | $2.58 M | $3.07 M |
| 08/10/2021 | Q2 2021 | -$0.12 | -$0.11 | 0.01 | $586,500 | $780,000 |
| 05/17/2021 | Q1 2021 | -$0.08 | -$0.13 | -0.05 | $34,000 | |
| 03/15/2021 | Q4 2020 | -$0.14 | $11,000 | |||
| 11/10/2020 | Q3 2020 | -$0.14 | -$0.05 | 0.09 | $1.82 M | $3.43 M |
| 08/10/2020 | Q2 2020 | -$0.13 | -$0.13 | 0 | $2.33 M | $354,000 |
| 05/08/2020 | Q1 2020 | -$0.09 | -$0.07 | 0.03 | $4.10 M | |
| 03/13/2020 | Q4 2019 | -$0.07 | $1.94 M |
Clearside Biomedical, Inc. Earnings: Frequently Asked Questions
-
When is Clearside Biomedical, Inc.'s earnings date?
Clearside Biomedical, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, November 12th, 2024 based off last year's report dates.
-
Did Clearside Biomedical, Inc. beat their earnings estimates last quarter?
In the previous quarter, Clearside Biomedical, Inc. (:CLSD) reported $-0.1 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.14 by $0.04.
-
How can I listen to Clearside Biomedical, Inc.'s earnings conference call?
The conference call for Clearside Biomedical, Inc.'s latest earnings report can be listened to online.
-
How can I read Clearside Biomedical, Inc.'s conference call transcript?
The conference call transcript for Clearside Biomedical, Inc.'s latest earnings report can be read online.
-
How much revenue does Clearside Biomedical, Inc. generate each year?
Clearside Biomedical, Inc. (:CLSD) has a recorded annual revenue of $8.23 M.
-
How much profit does Clearside Biomedical, Inc. generate each year?
Clearside Biomedical, Inc. (:CLSD) has a recorded net income of $8.23 M. Clearside Biomedical, Inc. has generated $-0.53 earnings per share over the last four quarters.
-
What is Clearside Biomedical, Inc.'s price-to-earnings ratio?
Clearside Biomedical, Inc. (:CLSD) has a price-to-earnings ratio of -2.53 and price/earnings-to-growth ratio is -0.25.
